MannKind Corp
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $4.28
- Today's High:
- $4.38
- Open Price:
- $4.34
- 52W Low:
- $2.91
- 52W High:
- $5.75
- Prev. Close:
- $4.35
- Volume:
- 1698484
Company Statistics
- Market Cap.:
- $1.17 billion
- Book Value:
- -0.971
- Revenue TTM:
- $158.12 million
- Operating Margin TTM:
- -15.05%
- Gross Profit TTM:
- $42.27 million
- Profit Margin:
- -30%
- Return on Assets TTM:
- -4.96%
- Return on Equity TTM:
- 0%
Company Profile
MannKind Corp had its IPO on 2004-07-28 under the ticker symbol MNKD.
The company operates in the Healthcare sector and Biotechnology industry. MannKind Corp has a staff strength of 391 employees.
Stock update
Shares of MannKind Corp opened at $4.34 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $4.28 - $4.38, and closed at $4.36.
This is a +0.23% increase from the previous day's closing price.
A total volume of 1,698,484 shares were traded at the close of the day’s session.
In the last one week, shares of MannKind Corp have slipped by -5.83%.
MannKind Corp's Key Ratios
MannKind Corp has a market cap of $1.17 billion, indicating a price to book ratio of 0 and a price to sales ratio of 16.5046.
In the last 12-months MannKind Corp’s revenue was $158.12 million with a gross profit of $42.27 million and an EBITDA of $-17257000. The EBITDA ratio measures MannKind Corp's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, MannKind Corp’s operating margin was -15.05% while its return on assets stood at -4.96% with a return of equity of 0%.
In Q2, MannKind Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 157.3%.
MannKind Corp’s PE and PEG Ratio
- Forward PE
- 303.0303
- Trailing PE
- 0
- PEG
- -0.23
Its diluted EPS in the last 12-months stands at $-0.18 per share while it has a forward price to earnings multiple of 303.0303 and a PEG multiple of -0.23. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into MannKind Corp’s profitability.
MannKind Corp stock is trading at a EV to sales ratio of 18.7073 and a EV to EBITDA ratio of -22.0202. Its price to sales ratio in the trailing 12-months stood at 16.5046.
MannKind Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $313.42 million
- Total Liabilities
- $96.97 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $16.87 million
- Dividend Payout Ratio
- 0%
MannKind Corp ended 2024 with $313.42 million in total assets and $0 in total liabilities. Its intangible assets were valued at $313.42 million while shareholder equity stood at $-260487000.00.
MannKind Corp ended 2024 with $0 in deferred long-term liabilities, $96.97 million in other current liabilities, 2682000.00 in common stock, $-3232529000.00 in retained earnings and $1.93 million in goodwill. Its cash balance stood at $86.18 million and cash and short-term investments were $144.35 million. The company’s total short-term debt was $26,353,000 while long-term debt stood at $352.16 million.
MannKind Corp’s total current assets stands at $230.23 million while long-term investments were $2.28 million and short-term investments were $58.16 million. Its net receivables were $27.79 million compared to accounts payable of $17.13 million and inventory worth $25.29 million.
In 2024, MannKind Corp's operating cash flow was $0 while its capital expenditure stood at $16.87 million.
Comparatively, MannKind Corp paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $4.36
- 52-Week High
- $5.75
- 52-Week Low
- $2.91
- Analyst Target Price
- $6.4
MannKind Corp stock is currently trading at $4.36 per share. It touched a 52-week high of $5.75 and a 52-week low of $5.75. Analysts tracking the stock have a 12-month average target price of $6.4.
Its 50-day moving average was $4.58 and 200-day moving average was $4.56 The short ratio stood at 11.35 indicating a short percent outstanding of 0%.
Around 262.5% of the company’s stock are held by insiders while 5388.9% are held by institutions.
Frequently Asked Questions About MannKind Corp
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company’s product pipeline also includes Tyvaso DP Treprostinil, an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease, and idiopathic pulmonary and cystic fibrosis. In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.